Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Astragaloside IV, a major active saponin isolated from the root of Astragalus membranaceus, has garnered scientific interest for its potential therapeutic effects in Chronic Obstructive Pulmonary Disease (COPD). Preclinical studies, primarily in animal models and in vitro systems, suggest that Astragaloside IV may exert anti-inflammatory and antioxidant effects, which are relevant to the pathophysiology of COPD. These studies have shown that Astragaloside IV can reduce levels of inflammatory cytokines (such as TNF-α and IL-6), inhibit oxidative stress, and attenuate airway remodeling and fibrosis in animal models of COPD. The proposed mechanisms include inhibition of the NF-κB signaling pathway and suppression of oxidative injury in lung tissues. However, direct clinical evidence in humans with COPD is lacking. There are no large-scale, high-quality randomized controlled trials evaluating the efficacy or safety of Astragaloside IV for COPD patients. Most available data come from laboratory research and a few small pilot studies or traditional use reports. As such, while there is a scientific rationale and promising preclinical data, the overall evidence remains weak and insufficient for recommendation in standard clinical practice. Further well-designed human studies are necessary to confirm its therapeutic potential and establish dosing and safety profiles in COPD.

More about Astragaloside IV
More about Chronic Obstructive Pulmonary Disorder

Other ingredients used for Chronic Obstructive Pulmonary Disorder

Other health conditions supported by Astragaloside IV

Products containing Astragaloside IV